BORIS的功能及相关药物研究进展  

Research progress on the functions of BORIS and related drug development

作　　者：徐东 卢多 XU Dong;LU Duo(State Key Laboratory of Active Substances and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,天然药物活性物质与功能国家重点实验室,北京100050

出　　处：《药学学报》2024年第7期1905-1915,共11页Acta Pharmaceutica Sinica

基　　金：中国医学科学院创新工程项目(2022-I2M-2-002)。

摘　　要：印记位点调节子的弟兄(brother of regulator of imprinted sites,BORIS)或者类CCCTC结合因子(CCCTC binding factor-like,CTCFL)是一个相对发现不久的癌症睾丸抗原。与之相关的药物研发已经在小分子、小RNA、多肽药、疫苗以及细胞等多个方向展开。因独特的干扰基因组空间高级结构的能力,BORIS可能代表着一类全新药物靶点。本综述系统梳理BORIS相关分子生物学研究结果,包括BORIS基因产物的多样性,由其介导的分子间互作,受到影响的信号传导通路,以及现有相关药物研发策略,以期明了BORIS的上下游调控分子机制及可能进一步突破的研究方向。Brother of regulator of imprinted sites(BORIS),also known as CCCTC binding factor-like(CTCFL),is a relatively newly discovered cancer-testis antigen.Drug development related to BORIS has been carried out in multiple directions,including small molecules,small RNA molecules,polypeptides,vaccines,and cellular therapies.Due to its unique ability to interfere with the higher-order spatial structure of the genome,BORIS may represent a new class of drug targets.Here we systematically review the molecular biology research results related to BORIS,including the diversity of its gene products,the multipartite interactions mediated by BORIS,the subsequent impact on signaling pathways,and current drug development strategies,in order to gain a better understanding of the molecular mechanisms of BORIS in both upstream and downstream regulation networks and to identify potential research directions for further breakthroughs.

关 键 词：BORIS 三维基因组结构 癌症睾丸抗原 分子机制 药物研发策略 

分 类 号：R966[医药卫生—药理学]